证券简称：开能健康 证券代码：300272 债券简称：开能转债 债券代码：123206 开能健康科技集团股份有限公司 向不特定对象发行可转换公司债券 2024 年度第四次临时受托管理事务报告 债券受托管理人 中国（上海）自由贸易试验区世纪大道 1198 号 28 层 二零二四年八月 重要声明 本报告依据《可转换公司债券管理办法》（以下简称"管理办法"）、《公司债 券受托管理人执业行为准则》《开能健康科技集团股份有限公司向不特定对象发 行可转换公司债券募集说明书》（以下简称"《募集说明书》"）、《开能健康科技集 团股份有限公司与长江证券承销保荐有限公司之可转换公司债券受托管理协议》 （以下简称"《受托管理协议》"）等相关规定、公开信息披露文件、开能健康科 技集团股份有限公司（以下简称"公司"、"开能健康"或"发行人"）出具的相 关说明文件以及提供的相关资料等，由受托管理人长江证券承销保荐有限公司 （以下简称"受托管理人"或"长江保荐"）编制。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为长江保荐所作的承诺 或声明。在任何情况下，未经长江 ...

3、赔偿限额：每次及累计赔偿限额为人民币 5,000 万元/年（具体以最终签 订的保险合同为准） | 证券代码：300272 | 证券简称：开能健康 | 公告编号：2024-070 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 开能健康科技集团股份有限公司 关于购买董监高责任险的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 开能健康科技集团股份有限公司（以下简称"公司"或"开能健康"）于2024 年8月26日召开第六届董事会第十六次会议及第六届监事会第十三次会议审议 《关于购买董监高责任险的议案》，为完善公司风险管理体系，保障公司董事、 监事及高级管理人员的权益，促进公司管理层充分行使权利、履行职责，营造公 司稳健发展的良好环境，促进公司健康发展，根据《上市公司治理准则》等有关 规定，公司拟为公司及全体董事、监事、高级管理人员及其他有关责任人购买责 任险。公司全体董事、监事均回避表决，该议案直接提交公司2024年第三次临时 股东大会审议。现将具体情况公告如下： 一、董监高责任险方案 1、投保人： ...

Financial Performance - Revenue for the first half of 2024 increased by 4.23% to 829,329,438.24 yuan compared to the same period last year[12] - Net profit attributable to shareholders rose by 6.04% to 57,031,840.79 yuan year-over-year[12] - Operating cash flow decreased by 30.78% to 119,957,275.03 yuan compared to the previous year[12] - Total assets grew slightly by 0.55% to 3,014,615,691.81 yuan as of the end of the reporting period[12] - Shareholders' equity decreased by 3.83% to 1,248,964,287.25 yuan compared to the end of the previous year[12] - The company expects a year-over-year decline in net profit for the first three quarters of 2024 due to non-recurring gains in 2023[3] - Revenue for the reporting period reached 829 million yuan, a year-on-year increase of 4.23%[51] - Net profit attributable to shareholders was 57.03 million yuan, up 6.04% year-on-year[51] - Non-GAAP net profit was 54.12 million yuan, an increase of 6.05% compared to the same period last year[51] - Gross margin for the period was 40.50%, up 2.27 percentage points year-on-year[51] - Revenue for the reporting period increased by 4.23% to 829,329,438.24 yuan compared to the same period last year[52] - Sales expenses decreased by 4.87% to 85,280,827.21 yuan, while management expenses increased by 9.42% to 113,180,931.02 yuan[52] - Financial expenses decreased significantly by 283.68% to -2,310,154.89 yuan due to the reversal of cash discounts[54] - Net cash flow from operating activities decreased by 30.78% to 119,957,275.03 yuan, primarily due to normalized inventory levels and increased employee compensation in North America[54] - Net cash flow from financing activities decreased by 227.67% to -79,785,774.72 yuan, mainly due to increased bank loan repayments and stock repurchases[54] - The gross profit margin for terminal business and services increased by 3.66% to 47.22%, despite a 4.30% decrease in revenue[55] - Revenue from intelligent manufacturing and core components increased by 22.45% to 320,559,611.50 yuan, with a gross profit margin increase of 1.47%[55] - The company's investment in Canature N.A. Inc. in Canada generated a net profit of 20,694,524.00 yuan, contributing 29.22% to the company's net assets[59] - Fixed assets increased by 2.18% to 301,725,037.54 yuan, mainly due to the transfer of subsidiary assets[58] - Inventory increased by 0.59% to 268,040,405.73 yuan, reflecting stable inventory levels after significant reductions in the previous period[58] - The company's financial assets totaled 7,099,661.67 yuan at the end of the period, with a slight increase of 1.82 yuan in fair value changes during the period[60] - Financial liabilities decreased by 4,689,310.59 yuan, primarily due to the impact of foreign exchange rate changes on minority shareholder put options from overseas acquisitions[60] - The company's inventory, valued at 113,199,941.67 yuan, was used as collateral for bank loans[61] - Fixed assets, including those used as collateral for bank loans, amounted to 113,418,150.88 yuan[63] - The company invested 37,566,490.97 yuan during the reporting period, an increase of 18.57% compared to the same period last year[64] - Significant ongoing non-equity investments include the Jiangsu Kaineng Huayu Water Reuse Project, with a cumulative investment of 79,375,770.41 yuan, and the Smart Upgrade of Healthy Water Equipment Production Line, with a cumulative investment of 40,666,512.53 yuan[65] - The company's total investment in fixed assets and expansion projects reached 120,042,282.94 yuan, with a realized profit of 2,961,762.94 yuan[66] - The company's financial assets, measured at fair value, showed no significant changes, with a total value of 7,099,661.67 yuan at the end of the period[67] - The company raised 250 million yuan through the issuance of convertible bonds, with a net amount of 244,007,441.89 yuan after deducting issuance costs[68] - The cumulative investment in promised projects using raised funds reached 90,597,900 yuan, with no changes in the intended use of the funds[69] - The total investment in the health water purification equipment production line digitalization upgrade and expansion project is RMB 20,000 million, with an investment progress of 20.33% as of June 30, 2024[70] - The company's total raised funds amount to RMB 25,000 million, with RMB 9,059.79 million already invested, achieving a cumulative benefit of RMB 296.18 million[70] - The actual balance of raised funds as of June 30, 2024, is RMB 161,247,275.65, stored in a dedicated account for future use according to project needs[71] - Canature N.A. Inc, a subsidiary, reported revenue of CAD 328,401,390.00 and net profit of CAD 20,694,524.00 in the reporting period[77] - Jiangsu Canature Huayu Environmental Equipment Co., Ltd, a subsidiary, achieved revenue of RMB 89,747,510.69 and net profit of RMB 14,864,603.16[75] - Zhejiang Runxin Electric Co., Ltd, a subsidiary, reported a net loss of RMB 14,703,732.08 with revenue of RMB 45,474,967.76[77] - Yuanneng Cell Technology Group Co., Ltd, a major equity investment, reported a net loss of RMB 13,934,253.41 with revenue of RMB 79,703,004.59[77] - Shanghai Yuanneng Cell Biological Low-Temperature Equipment Co., Ltd, a subsidiary, reported a net loss of RMB 34,110,483.51 with revenue of RMB 43,954,771.74[77] - The company holds a 36.5167% stake in Yuanneng Cell Technology Group Co., Ltd, which focuses on cell technology and health-related industries[78] - Yuanneng Group is engaged in the development and manufacturing of automated, intelligent deep-low-temperature biological storage equipment, a key area in the biopharmaceutical industry[79] - Yuanneng Bio has successfully developed and launched multiple series of automated biological sample (cell) storage equipment, including BSN, BSE, P, AR, and AM series, catering to different industry needs[80] - Yuanneng Bio has accumulated 476 patent applications globally, including 14 PCT international patents and 27 foreign patents, with 389 patents authorized[82] - Yuanneng Bio has obtained ISO9001, ISO13485, GB/T 23001, GB/T29490, ISO45001, and ISO14001 certifications, ensuring high-quality management systems[82] - Yuanneng Bio's cell factory, built to GMP standards, covers 2,000 square meters, including a 1,500-square-meter cell preparation center and a 500-square-meter quality inspection area[85] - The company has established a fully automated 5G cell library in Zhangjiang, integrating AI, VR/AR, and human-computer interaction technologies, ensuring sample quality and safety[87] - Yuanneng Group has launched a "1+N" cell library development plan, aiming to build regional cell libraries in key cities across China, with strategic partnerships in Kunming, Lishui, and Baoji[88] - Yuanneng Group operates three industrial parks in Zhangjiang, covering a total area of 80,000 square meters, housing a cell life science museum and supporting facilities[89] - Yuanneng Group's subsidiary, Jiyuan Beauty, has developed a series of skincare products using advanced protein recombination and compounding technologies, with core products certified by SGS and CTI[91] - Yuanneng Bio has been recognized as a national high-tech enterprise and a "Little Giant" enterprise, with multiple awards for innovation and technology development[80][81] - The company has established a comprehensive cell industrialization system, focusing on automated, intelligent, and clinical-grade cell storage and application processes[80] - The experimental animal center construction by Shanghai Laisen Yuan Life Science Co., Ltd., a wholly-owned subsidiary of Yuanneng Group, has completed its infrastructure preparation and obtained the experimental animal use license in February 2024, officially commencing services[92] - Yuanneng Group indirectly holds a 15.61% stake in Xingya Aviation through its subsidiaries, with Xingya Aviation having a registered capital of 74.274 million yuan[92] - Xingya Aviation operates a fleet including global mainstream private jet brands such as Gulfstream, Bombardier, Dassault, and Hawker Beechcraft, and owns one Cirrus SR20 small fixed-wing aircraft[93] - Xingya Aviation has obtained IS-BAO Stage III certification and holds operational and maintenance qualifications in multiple countries including China, the US, and the Cayman Islands[93] - Xingya Aviation's subsidiary, Xingya Low-Altitude Express, is a pioneer in Central Business District helicopter FBOs in China, offering services such as helicopter charter flights and air ambulance[94] - The company faces intense competition in the Chinese residential water treatment equipment industry, with potential risks to future operating performance if it cannot maintain its competitive edge[95] - The company's overseas sales account for a significant portion, with potential risks from market fluctuations in North America and Europe[97] - The company is exposed to risks from changes in international trade policies, including potential tariffs and import restrictions, which could impact its overseas operations and export performance[98] - The company faces foreign exchange risk due to its significant overseas sales, primarily denominated in USD, and employs strategies such as hedging and timely currency settlement to mitigate this risk[99] - The company's new RO membrane reverse osmosis water purifier production line project aims to add 700,000 units of capacity, with potential risks from market competition and slower-than-expected sales growth[103] - The company held a temporary shareholders' meeting on January 15, 2024, with a participation rate of 34.82%, approving a special dividend plan for shareholders[108] - A second temporary shareholders' meeting was held on March 12, 2024, with a participation rate of 36.42%, approving revisions to the board meeting rules and articles of association[108] - The 2023 annual shareholders' meeting was held on May 16, 2024, with a participation rate of 42.92%, approving the 2023 annual report, financial report, and profit distribution plan[108] - The company announced a semi-annual profit distribution plan on August 26, 2024, proposing a cash dividend of RMB 0.5 per 10 shares, totaling RMB 28,253,169.55[110] - The total cash dividend, including other methods, amounts to RMB 57,309,872.6, accounting for 100% of the total profit distribution[110] - The company's distributable profit stands at RMB 230,208,086.21[110] - The company conducted multiple investor meetings and communications throughout the first half of 2024, discussing business operations and development plans[106] - The company disclosed its "Quality and Return Dual Improvement" action plan on April 23, 2024[107] - The company's board of directors approved a mid-term dividend authorization for 2024 during the annual shareholders' meeting[108] - The company plans to apply for a comprehensive credit line from banks and other financial institutions in 2024[108] - The company's employee stock ownership plan involves 141 employees holding a total of 10,370,000 shares, accounting for 1.80% of the company's total share capital[111] - The company confirmed a total of 11.8564 million yuan in capital reserve from equity-settled share-based payments, with 1.6938 million yuan in 2023 and 10.1626 million yuan in the first half of 2024[113] - The company has implemented measures to reduce carbon emissions, including increasing the use of green raw materials, improving energy efficiency, and adopting eco-friendly packaging materials[115] - The company's CS20H water softener received a product carbon footprint assessment report from SGS in 2022, providing a reference standard for low-carbon environmental protection[116] - The company was awarded the national "Green Factory" title in 2023[116] - The company's actual controller, Qu Jianguo, has committed to abstaining from voting rights for 28,390,000 shares (approximately 7.13% of the total shares) since December 25, 2017, and this commitment remains effective as of the reporting period[117] - Qu Jianguo further committed to abstaining from voting rights for an additional 13,450,000 shares (approximately 2.31% of the total shares) on April 10, 2020, and this commitment is also effective as of the reporting period[117] - Qu Jianguo has made a long-term commitment to avoid同业竞争 (same-industry competition) since November 2, 2011, and no violations were found as of the reporting period[117] - Qu Jianguo has committed to minimizing关联交易 (related-party transactions) since November 2, 2011, and no violations were found as of the reporting period[117] - Qu Jianguo has made a承诺 (commitment) not to reduce his holdings of the company's shares under certain conditions since July 10, 2015, and no violations were found as of the reporting period[118] - The company reported no non-operational占用资金 (fund occupation) by controlling shareholders or related parties during the reporting period[118] - The company reported no违规对外担保 (illegal external guarantees) during the reporting period[119] - The company's半年度财务报告 (semi-annual financial report) was not audited[119] - The company reported no重大诉讼仲裁事项 (major litigation or arbitration matters) during the reporting period[119] - The company reported no重大关联交易 (major related-party transactions) during the reporting period[120] - The company's total actual guarantee amount (A4+B4+C4) accounts for 2.88% of the company's net assets[126] - The company has a total approved guarantee amount of 9,500, with an actual guarantee balance of 3,600[125] - The company completed a share repurchase of 7.0574 million shares, accounting for 1.2227% of the total shares, with a total repurchase amount of 29.0567 million yuan[133] - The company's convertible bonds have a conversion period from January 26, 2024, to July 19, 2029, with an adjusted conversion price of 5.62 yuan per share[134] - The company's employee持股计划 received 10.37 million shares at a transfer price of 4.31 yuan per share, with a lock-up period until December 20, 2024[130] - The company's total approved guarantee amount for subsidiaries is 8,000, with an actual guarantee balance of 3,600[125] - The company's convertible bonds had a face value of 24,500 yuan converted during the first quarter of 2024[135] - The company's total approved guarantee amount for external entities is 1,500, with no actual guarantee balance[124] - The company's share repurchase plan was adjusted to include the conversion of convertible bonds, with a total of 12.15452 million shares held in the repurchase account[133] - Cumulative conversion of "Kaineng Convertible Bonds" to common stock reached 45,962 shares, with the remaining unconverted bonds valued at 249.74 million yuan, accounting for 99.90% of the total issuance[136][137][138] - The total number of shares increased by 45,962 due to the conversion of convertible bonds, resulting in a total share count of 577,217,911 shares[137] - The diluted earnings per share for the first half of 2024 were 0.0947 yuan per share, and the net asset per share attributable to common shareholders was 2.16 yuan[139] - The company's limited-sale shares remained unchanged at 146,097,457 shares, representing 25.31% of the total shares[137] - The company's unrestricted shares increased by 45,962 shares to 431,120,454 shares, maintaining a 74.69% share of the total[137] - The company's top shareholder, Qu Jianguo, holds 145,978,657 shares, accounting for 25.29% of the total shares, with these shares being locked as executive shares[139] - The company's total number of common shareholders at the end of the reporting period was 26,997[140] - Qu Jianguo has relinquished voting rights for 54,331,600 shares, representing 9.4127% of the company's total shares[142] - The company's top 10 shareholders include a repurchase account holding 12,154,520 shares[142] - The company's controlling shareholder, Qu Jianguo, holds 33.72% of the shares, totaling 194,638,209 shares, with 48,659,552 shares being unrestricted[144][145] - The Shanghai Jianguo Social Welfare Foundation holds 5.70% of the shares, totaling 32,896,593 shares, all of which are unrestricted[144][145] - The company's employee stock ownership plan holds 1.80% of the shares, totaling 10,370,000 shares, all of which are unrestricted[144][145] - The company's convertible bond, "Kaineng Convertible Bond," has a total issuance amount of 250,000,000 RMB, with a cumulative conversion amount of 256,900 RMB, representing 0.01% of the total shares before the conversion period[153] - The conversion price of the "Kaineng Convertible Bond" was adjusted from 5.67 RMB/share to 5.62 RMB/share on January 24, 2024, due to a special dividend distribution[150][151] - The conversion price of the "Kaineng Convertible Bond" was further adjusted from 5.62 RMB/share to 5.52 RMB/share on May 28, 2024, due to the 2023 annual dividend distribution[152] - The company's shareholder, Guo Xiuzhen,

开能健康科技集团股份有限公司（以下简称"开能健康"） 于 2024 年 4 月 19 日召开第六届董事会第十四次会议及第六届监事会第十一次会议，审议通过《关 于 2024 年日常关联交易预计的议案》，公司及其控股子公司预计 2024 年度将与 关联方发生关联交易总金额约为 2,450 万元。具体内容请见公司在巨潮资讯网披 露的《关于 2024 年度日常关联交易预计的公告》（公告编号：2024-037）。 （二）本次预计新增日常关联交易情况 1、2024 年上半年，公司关联方上海原能细胞生物低温设备有限公司完成并 购原本公司之非标自动化设备供应商，导致公司增加了新的关联方，公司预计增 加与上海原能细胞生物低温设备有限公司及其子公司（以下简称"原能生物及其 子公司"）发生的日常关联交易总金额不超过 3,000 万元。 2、本次新增日常关联交易预计已经 2024 年 8 月 26 日召开的公司第六届董 事会第十六次会议及第六届监事会第十三次会议审议通过，公司关联董事瞿建国 先生、瞿亚明先生已回避表决。该议案已经公司董事会独立董事专门会议审议通 过，保荐机构就上述事项发表了无异议的核查意见。 | 证券代码：30027 ...

| 证券代码：300272 | 证券简称：开能健康 | 公告编号：2024-068 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 开能健康科技集团股份有限公司 关于继续使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 开能健康科技集团股份有限公司（以下简称"公司"或"开能健康"）于2024 年8月26日召开了第六届董事会第十六次会议及第六届监事会第十三次会议，审 议通过《关于继续使用部分闲置募集资金进行现金管理的议案》，同意公司继续 使用不超过2亿元（含本数）的闲置募集资金进行现金管理，使用期限自公司董 事会审议通过之日起 12 个月内有效。在上述额度和期限范围内，资金可以循环 滚动使用。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意开能健康科技集团股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕1321号）同意注 册，公司向不特定对象发行可转换债券募集资金总额共计人民币 250,000,000 元， ...

证券代码：300272 证券简称：开能健康 公告编号：2024-066 债券代码：123206 债券简称：开能转债 开能健康科技集团股份有限公司 2024 年半年度利润分配预案公告 1、每10股分配比例：每10股派发现金红利人民币0.5元（含税），不送红股， 不以资本公积金转增股本。 2、若实施权益分派股权登记日前总股本发生变动的，公司将按照每股分红 金额不变的原则对分红总额进行调整。 3、本次利润分配以实施权益分派时股权登记日登记的总股本扣除公司回购 专用证券账户中的股份为基数，具体日期将在权益分派实施公告中明确。 4、2024年中期分红安排已经2023年度股东大会审议通过，本次利润分配事 项无需再提交股东大会审议。 开能健康科技集团股份有限公司（以下简称"公司"）第六届董事会第十六 次会议审议通过《2024年半年度利润分配预案》，具体公告如下： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、2024年半年度利润分配预案 开能健康科技集团股份有限公司（以下简称"公司"）2024年半年度公司合 并报表归属于母公司所有者的净利润为人民币 57, ...

长江证券承销保荐有限公司 关于开能健康科技集团股份有限公司 新增 2024 年度日常关联交易预计的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"或"保荐机构"）作为开 能健康科技股份有限公司（以下简称"开能健康"或"公司"）向不特定对象发行 可转换公司债券的持续督导保荐机构，依据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》等有关规定，对开能健康新增 2024 年度日常 关联交易预计事项进行了审慎核查，具体情况如下： 公司于 2024 年 4 月 19日召开第六届董事会第十四次会议及第六届监事会第十一 次会议，审议通过《关于 2024 年日常关联交易预计的议案》，公司及其控股子公司 预计 2024 年度将与关联方发生关联交易总金额约为 2,450 万元。具体内容请见公司 在巨潮资讯网披露的《关于 2024 年度日常关联交易预计的公告》（公告编号： 2024-037）。 一、日常关联交易基本情况 （一）公司已预计的 2024 年日常关联交易的情况 （二）本次预计新增日常关联交易情况 1、2024年上半年 ...

证券代码：300272 证券简称：开能健康 公告编号：2024-063 债券代码：123206 债券简称：开能转债 开能健康科技集团股份有限公司 第六届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 与会各位监事对本次监事会会议议案进行了认真审议，以现场结合通讯表决 方式进行了表决，且通过了以下决议： 1、开能健康科技集团股份有限公司（下文简称"公司"）第六届监事会第十 三次会议的会议通知于2024年8月16日以邮件方式发出。 2、本次监事会会议于2024年8月26日在上海市浦东新区川大路518号本公司 会议室，以现场结合通讯表决方式召开。 3、本次监事会会议应出席监事3名，实际出席监事3名。 4、本次监事会会议由监事会主席周斌先生主持。 5、本次监事会会议的召集、召开符合《公司法》等有关法律、法规和《公 司章程》的规定。 二、监事会会议决议情况 1、会议以 3 票同意，0 票反对，0 票弃权，审议通过了《2024年半年度报 告》全文及其摘要； 经审核，监事会认为：董事会编制和审核公司2024年半年度报告的程 ...

长江证券承销保荐有限公司 关于开能健康科技集团股份有限公司 继续使用部分闲置募集资金进行现金管理的核查意见 作为开能健康科技集团股份有限公司（以下简称"开能健康"或"公司") 持续督导的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券交易 所创业板股票上市规则》等文件的规定，长江证券承销保荐有限公司（以下简称 "长江保荐"或"保荐人"）对开能健康关于使用部分闲置募集资金进行现金 管理进行了核查，具体核查情况如下： 单位：万元 | 序 | 项目名称 | 项目预计总投入金 | 拟投入本次募集资金金 | | --- | --- | --- | --- | | 号 | | 额 | 额 | | 1 | 健康净水装备生产线数智化升级及扩建 | 20,901.56 | 20,000.00 | | | 项目 | | | | 2 | 补充流动资金 | 5,000.00 | 5,000.00 | | | 合计 | 25,901.56 | 25,000.00 | 目前，公司正按照募集资金使用计划有序推进募投项目的进展。因募投项目的 建设需要一定的周期 ...

| 证券代码：300272 | 证券简称：开能健康 公告编号：2024-061 | | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | 开能健康科技集团股份有限公司 关于回购公司股份实施结果暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、公司回购公司部分社会公众股份方案实施结果：实际回购时间区间为 2024 年 2 月 6 日至 2024 年 2 月 20 日。截至本公告披露日，公司根据本次回购 股份方案通过股票回购专用证券账户以集中竞价交易方式累计回购公司股份 705.74 万股，占公司当前总股本的 1.2227%，最高成交价为 4.446 元/股，最低成 交价为 3.84 元/股，支付的总金额为 2,905.67 万元（不含交易费用）。 2、本次回购方案实际执行情况，包括股份数量、回购价格、回购股份的实 施期限以及资金来源等，与原披露的回购方案不存在差异。至此，公司本次股份 回购方案实施完毕。 ① 经 2024 年 7 月 17 日召开的第六届董事会第十五次会议审议通过《关于变更回购公司 ...